BRCA1 and breast carcinoma: Reconstitution of wild-type BRCA1 into BRCA1-negative HCC1937 breast cancer cells resulted in a 20-fold increase in cisplatin resistance and, in contrast, a 1000- to 10 000-fold increase in sensitivity to paclitaxel and vinorelbine (Quinn et al, 2003).